These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37328323)

  • 41. Effect of long-term GH replacement therapy on cardiovascular outcomes in GH-deficient patients previously treated for acromegaly: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Bunderen CC; van Varsseveld NC; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Eur J Endocrinol; 2014 Dec; 171(6):717-26. PubMed ID: 25227133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of growth hormone stimulation tests in cured acromegalic patients.
    Conceição FL; Fisker S; Andersen M; Kaal A; Jørgensen JO; Vaisman M; Christiansen JS
    Growth Horm IGF Res; 2003 Dec; 13(6):347-52. PubMed ID: 14624769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sweat secretion rates in growth hormone disorders.
    Sneppen SB; Main KM; Juul A; Pedersen LM; Kristensen LO; Skakkebaek NE; Feldt-Rasmussen U
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):601-8. PubMed ID: 11106921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
    Ahmad AM; Hopkins MT; Thomas J; Ibrahim H; Fraser WD; Vora JP
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):709-17. PubMed ID: 11422104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IGF-1 as screening tool for acromegaly and adult-onset growth hormone deficiency in the Netherlands.
    Postma MR; van Beek AP; van der Klauw MM; Lentjes EGWM; Muller Kobold AC
    Clin Endocrinol (Oxf); 2024 Mar; 100(3):260-268. PubMed ID: 38044875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
    Arafah BM; Rosenzweig JL; Fenstermaker R; Salazar R; McBride CE; Selman W
    J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency.
    Miljic D; Miljic P; Doknic M; Pekic S; Stojanovic M; Cvijovic G; Micic D; Popovic V
    Growth Horm IGF Res; 2013 Dec; 23(6):243-8. PubMed ID: 24041757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments.
    Ronchi CL; Giavoli C; Ferrante E; Verrua E; Bergamaschi S; Ferrari DI; Corbetta S; Montefusco L; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    Eur J Endocrinol; 2009 Jul; 161(1):37-42. PubMed ID: 19351744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life of growth hormone (GH) deficient young adults during discontinuation and restart of GH therapy.
    Stouthart PJ; Deijen JB; Roffel M; Delemarre-van de Waal HA
    Psychoneuroendocrinology; 2003 Jul; 28(5):612-26. PubMed ID: 12727130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
    Gómez JM; Gómez N; Fiter J; Soler J
    Horm Metab Res; 2000 Feb; 32(2):66-70. PubMed ID: 10741688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients.
    Charalampaki P; Hildebrandt G; Schaeffer HJ; Schönau E; Klug N
    Exp Clin Endocrinol Diabetes; 1998; 106(2):130-4. PubMed ID: 9628244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Benefits and risks of growth hormone in adults with growth hormone deficiency].
    Díez JJ; Cordido F
    Med Clin (Barc); 2014 Oct; 143(8):354-9. PubMed ID: 24485161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dyslipidaemia and growth hormone deficiency - A comprehensive review.
    Hepprich M; Ebrahimi F; Christ E
    Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101821. PubMed ID: 37821339
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of growth hormone in adults: a review of the last 10 years, the present and a perspective for the future.
    Bengtsson BA; Johannsson G
    Growth Horm IGF Res; 1998 Apr; 8 Suppl B():27-35. PubMed ID: 10990133
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment Factors That Influence Mortality in Acromegaly.
    McCabe J; Ayuk J; Sherlock M
    Neuroendocrinology; 2016; 103(1):66-74. PubMed ID: 25661647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
    van der Lely AJ; Hutson RK; Trainer PJ; Besser GM; Barkan AL; Katznelson L; Klibanski A; Herman-Bonert V; Melmed S; Vance ML; Freda PU; Stewart PM; Friend KE; Clemmons DR; Johannsson G; Stavrou S; Cook DM; Phillips LS; Strasburger CJ; Hackett S; Zib KA; Davis RJ; Scarlett JA; Thorner MO
    Lancet; 2001 Nov; 358(9295):1754-9. PubMed ID: 11734231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.